This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Alnylam's Kidney Disease Drug Succeeds in Late Stage Study
by Zacks Equity Research
Alnylam (ALNY) reports positive top-line results from the phase III study on lumasiran for the treatment of primary hyperoxaluria type 1.
Pfizer Gets CHMP Nod for Vyndaqel Label Expansion in Europe
by Zacks Equity Research
Pfizer (PFE) receives a positive CHMP opinion recommending approval for once-daily Vyndaqel (61mg) oral capsule to treat hereditary transthyretin amyloid cardiomyopathy in adult patients.
Here's Why Momentum Investors Will Love Alnylam Pharmaceuticals (ALNY)
by Zacks Equity Research
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Alnylam (ALNY) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Trade of the 2020's: Sell Gold, Buy Biotech
by Kevin Cook
In 5 years, you be selling your gold and buying more companies leading the century of biology.
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: GLD, CRSP, GBT, ALNY and ARKG
Alnylam Gets Second Product Approval Amid Stiff Competition
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
Why Gold is Headed to Zero -- And What You Should Buy Instead
by Kevin Cook
In 2026, NASA mission Psyche will explore an asteroid that could hold over $5,000 quadrillion in gold
Alnylam Pharmaceuticals, Inc. (ALNY) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Alnylam Pharmaceuticals, Inc. (ALNY).
The Medicines Company to be Acquired by Novartis for $9.7B
by Zacks Equity Research
The Medicines Company (MDCO) agrees to the $85 per share or $9.7-billion acquisition offer from Novartis.
Alnylam's Givosiran Gets FDA Nod for Acute Hepatic Porphyria
by Zacks Equity Research
Alnylam (ALNY) gets FDA approval for givosiran injection, to be marketed by the trade name of Givlaari, for the treatment of adults with AHP.
Alnylam (ALNY) Catches Eye: Stock Jumps 10.5%
by Zacks Equity Research
Alnylam (ALNY) saw a big move last session, as its shares jumped nearly 11% on the day, amid huge volumes.
Medicines Company Up on Rumors of Potential Buyout by Novartis
by Zacks Equity Research
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
Medicines Company Posts Full Inclisiran Data From ASCVD Study
by Zacks Equity Research
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
Alnylam Pharmaceuticals (ALNY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Alnylam Pharmaceuticals (ALNY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Alnylam (ALNY) Upgraded to Buy: Here's Why
by Zacks Equity Research
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Regeneron's (REGN) Q3 Earnings Beat on Dupixent Strength
by Zacks Equity Research
Regeneron (REGN) beats on Q3 earnings and sales on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.
Alnylam's (ALNY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alnylam (ALNY) incurs narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss
by Zacks Equity Research
The Medicines Company (MDCO) misses earnings estimates in Q3. The company is progressing well with its sole pipeline candidate, inclisiran.
Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alnylam (ALNY) delivered earnings and revenue surprises of 11.52% and 14.15%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Guardant Health (GH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q3 conference call, investors will watch out for the latest news on the colorectal cancer screening rates of its LUNAR-2 blood test.
Why Earnings Season Could Be Great for Alnylam (ALNY)
by Zacks Equity Research
Alnylam (ALNY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings.
Catalyst Pharma (CPRX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
During Catalyst's (CPRX) third-quarter 2019 conference call, investor focus will be on the sales performance of its only marketed drug Firdapse and its label expansion studies.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings?
by Zacks Equity Research
During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.